

## Results of 2022 Annual General Meeting

---

ASX Market Announcements Office  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

The results of Resonance Health Ltd's Annual General Meeting held at 10:00am WST on 24 November 2022 are set out in the attached document. All resolutions put to the AGM were decided by a poll.

For further information please contact:  
**Liesl Ellies** – General Counsel & Company Secretary  
E: [liesle@resonancehealth.com](mailto:liesle@resonancehealth.com)  
P: +61 (0)8 9286 5300

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

### About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of non-invasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high-quality quantitative measurements essential in the management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. A number of these SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan®** - provides an accurate measurement of liver iron concentration (**LIC**) through a non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. FerriScan is internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®** - an AI-driven system for the automated real-time measurement of LIC in patients using non-invasive MRI-based technology.
- **HepaFat-AI®** - an AI-driven system for the automated real-time multi-metric measurement of liver fat in patients using non-invasive MRI-based technology, for use in the assessment of individuals with confirmed or suspected fatty liver disease.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **Alert-PE**, an AI tool for the automated review of chest CT scans of patients with suspected pulmonary embolism.

## Results of Annual General Meeting held on 24 November 2022

Resolutions voted on at the meeting					Votes cast on the poll					Proxies received			
Resolution		Result	Voting method	If s250U applies	Voted for		Voted against		Abstained*	For	Against	Abstain	Discretion
No	Short description				Number	%	Number	%		Number	Number	Number	Number
1	Remuneration Report (Ordinary resolution)	Carried	Poll	N/A	63,478,602	92.93	4,826,369	7.07	361,000	61,448,529	4,826,369	11,000	1,301,915
2	Re-election of Director – Dr Travis Con Baroni (Ordinary resolution)	Carried	Poll	N/A	144,111,879	96.93	4,568,769	3.07	350,000	142,092,206	4,568,769	0	1,291,515
3	Approval of 10% Placement Facility (Special resolution)	Carried	Poll	N/A	147,486,285	98.97	1,536,763	1.03	7,600	145,116,612	1,536,763	7,600	1,291,515
4	Re-insertion of Proportional Takeover Bid Approval Provisions (Special resolution)	Carried	Poll	N/A	148,211,279	99.47	788,769	0.53	30,600	145,825,476	788,769	30,600	1,307,645
5	Approval to issue performance rights to a Director (Ordinary resolution)	Carried	Poll	N/A	62,068,159	90.87	6,237,569	9.13	360,243	57,882,956	5,614,569	10,243	4,080,045

\*Votes cast by a person who abstain on an item are not counted in calculating the required majority on a poll.